Register Here

2019 Executive Sponsors

Cofactor Genomics
IsoPlexis
Mitra Biotech
Personalis

2019 Associate Sponsors

Adaptive Biotech
Biodesix
Fate Therapeutics
Imaging Endpoints
Invicro
IQVIA
Precision for Medicine
Tempus

2019 Educational Partners

Alliance for Regenerative Medicine (ARM)
Journal of Immunotherapy and Precision Oncology (JIPO)
SITC

2019 Supporting Partner

Center for Biotechnology

2019 Media Partners

Big4Bio
Clinical Leader
Pharmalicensing

Overview

The Latest Data Impacting Immuno-oncology Combinations and Patient Treatment
Perspectives Representing Science, Clinical and Business


The 4th annual IO Combinations 360° program addresses business aspects, clinical advancements and scientific data in IO combination strategies. The rapid advancement in our understanding of human cancer immunity and immunotherapy combinations is nearly impossible for individual scientists to comprehend. Only together, as an engaged and interactive scientific community, can we hope to enable a patient’s immune system to eradicate cancer.

IO Combinations 360° delivers three key benefits:

  1. Access to KOLs driving the science
  2. Partnership opportunities with all stakeholders in Immuno-Oncology & Combinations
  3. Presentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology Combinations

2019 Keynotes

Clinical Trials of Double Chimeric Antigen Receptor (CAR) T Cells and Engineered T Cell Combination Therapies

Bruce Levine, PhD
University of Pennsylvania

Hubble’s Constant for the Expanding Universe of Immunotherapy

Drew Pardoll, MD, PhD
Johns Hopkins University School of Medicine

Key Topic Areas for 2019


  • Discovery / Preclinical Science
  • Bispecifics
  • Translational Science & Biomarkers
  • Next Generation Cell Therapy
  • Clinical Developments
  • Operationalizing Combinations
  • Business Aspects
  • Emerging Technologies

 

  We are delighted to
  Welcome the Merck Team to Include Representation from:

 

Roy Baynes, MD, PhD
SVP, Global Clinical Development, Merck

 

Andy Lee
SVP, Head of Global Clinical Trial Operations, Merck

 

Carol Haddad
Director, Global Clinical Supply Planning, Merck

 

Emmett Schmidt, MD, PhD
Scientific Associate VP; Lead, External Collaborations Project Team, Merck

 

  Covering the following topics:

  • Pembrolizumab as a Foundational Partner for Combination Immune-Oncology Drug Development
  • Emerging Results in the IO Field on PD1 Checkpoint Inhibitor Combination Therapy
  • Addressing Operational Challenges of Multi-therapy Combination Studies

 

Additional Featured Speakers

 

IO Combinations 360° provides the most up-to-date research, data and progress on combination developments to help IO stakeholders:

  • Be at the forefront of the most relevant research and developments for IO combinations from key leadership who are at the pulse of cancer immunotherapy
  • Foster collaboration amongst others working in all aspects of cancer immunotherapy by rounding up all stakeholders under one roof
  • Receive the latest pre-clinical, translational and clinical data from academia and industry
  • Better understand what assets are available for potential combinations that may be able to give patients more treatment options
  • Create and prioritize combination strategies targeted toward specific tumor types
  • Get key investor and analyst evaluations and insights on the IO combination landscape
  • Learn about biomarker advancements, neoantigen approaches and more
  • Obtain coverage on a wide range of emerging technologies

Dr Dan Chen, IGM Biosciences, presented on Novel Approaches to Engineered Cancer Immunotherapy at IO Combinations 360° 2018

Dr Steven Rosenberg, NCI delivered a Keynote on Lymphocytes as a Drug for the Treatment of Metastatic Cancer at IO Combinations 360° 2018

Dr Patrick Hwu, MD Anderson led a panel on Scalability of T-Cell Therapy with Dr Steven Rosenberg, NCI, Dr Maria Fardis, IOVance, Dr Roger Sidhu, Kite, Dr Rafael Amado, Adaptimmune, Dr Dan Chen, IGM Biosciences at IO Combinations 360° 2018

Dr Ian McCaffery, Janssen led a panel on Predicting IO Combination Success with Dr Theresa LaVallee, Parker Institute for Cancer Immunotherapy, Dr Patrick Hwu, MD Anderson and Dr Marcus Bosenberg, Yale Cancer Center at IO Combinations 360° 2018

 

If you are interested in participating in the 4th annual IO Combinations 360° program, please contact Kate Woda at Kate@tcfllc.org.

Sincerely,

Kate-BW-2

Kate Woda
Conference Director

Valerie Bowling New

Valerie Bowling
Executive Director

Meredith-2018

Meredith Sands
Executive Director, Business Development

Elizabeth Bard B&W-47

Elizabeth Bard
Business Development Manager

geeta-new-bw

Geeta Bachani
Business Development Manager

Meg

Meg Gould
Senior Conference Planner

Bre

Bre Bugbee
Marketing Manager

 

Testimonials

  • "By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there’s quite a lot of folks participating who are not traditionally talking to one another on a daily basis."

    - Roy Baynes, Merck Research Labs

  • "I absolutely enjoyed the meeting! It was great getting both academia and industry together to discuss how we move forward."

    - Robert Andtbacka, Huntsman Cancer Institute

  • "Thanks so much for putting on a great conference. It was very informative and I was excited to be a part of it. I am looking forward to the next one!"

    - Amanda Bruno, GSK

  • "It was a great conference. I learned a lot and enjoyed the diversity of speakers"

    - Julia Keith, RA Capital

  • "It was great meeting. I really enjoyed the conference and my interactions with several of the participants."

    - Jeffrey Wallin, Genentech